All In Biotech

Drug Trial Radar · NCT01214850

Novartis Vaccine and Diagnostics Carriage Trial

A Phase 3 Observer Blind Randomized, Multi-center, Controlled Study to Evaluate the Effect of Novartis Vaccine's Meningococcal B Recombinant and MenACWY Conjugate Vaccines on Pharyngeal Carriage of N. Meningitidis in Young Adults

Last checked: Nov 19, 2026Latest source record: Apr 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,968 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,968

Actual

Start

Sep 2010

Primary completion

Jan 2012

Study completion Jan 2012

Sponsor

Lead sponsor
Novartis VaccinesNovartis (NVS)
Sponsor type
Industry
First posted
Oct 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 24 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this trial was to evaluate the effect of Novartis Vaccine's Meningococcal vaccines on carriage of Neisseria meningitidis in a young adult population.

Conditions

  • N. Meningitidis Carriage

Interventions

  • Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)Biological

  • MenACWY-CRM conjugate vaccineBiological

  • Japanese Encephalitis vaccineBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ VaccinationTime frame: 61 days (31 days after receiving the second injection)
  2. Percentages of Subjects With Combined Carriage of N. Meningitidis Serogroups A, C, W and Y, One Month After MenACWY-CRM VaccinationTime frame: 31 days after MenACWY-CRM injection

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Bristol Children's Vaccine Center, University of Bristol,

    Bristol, England, United Kingdom

  • Royal Liverpool and Broad Green University Hospital Trust

    Liverpool, England, United Kingdom

  • St Georges Vaccine Institute, St Georges, University of London

    London, England, United Kingdom

  • Manchester Welcome Trust Clinical Research Facility, University of Manchester

    Manchester, England, United Kingdom

  • The James Cook University Hospital

    Middlesbrough, England, United Kingdom

  • Cripps Health Centre, University Park

    Nottingham, England, United Kingdom

  • University of Oxford, Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine

    Oxford, England, United Kingdom

  • Clinical Research Facility, Royal Hallamshire Hospital

    Sheffield, England, United Kingdom

  • Wellcome Trust Clinical Research Facility, University of Southampton

    Southampton, England, United Kingdom

  • Clinical Research Center, University of Surrey

    Surrey, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.